DNA Script extends Series B

Paris-based DNA Script, a DNA synthesis company, has raised $50 million as an extension to its Series B funding, expanding the round to $89 million.

Paris-based DNA Script, a DNA synthesis company, has raised $50 million as an extension to its Series B funding, expanding the round to $89 million. Casdin Capital led the round. In addition to the funding, Eli Casdin, founder and chief investment officer of Casdin Capital, will join DNA Script’s board of directors.

Source: Press Release